An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation

Heart

Volumn 82, Issue 2, 1999, Pages 170-175

  Steeds, R P ^a   Birchall, A S ^a   Smith, M ^b   Channer, K S ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b ROTHERHAM GENERAL HOSPITAL   (United Kingdom)

Author keywords

Atenolol; Paroxysmal atrial fibrillation; Sotalol

Indexed keywords

ATENOLOL; SOTALOL;

ADULT; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; ELECTROCARDIOGRAM; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032782617     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.82.2.170     Document Type: Article

References (30)

1. Channer KS, Jones JV. Atrial systole: its role in normal and diseased hearts. Clin Sci 1988;75:1-4.
2. Kannel WB, Abbot RD, Savage DD, et al. Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J 1983;106:389-96.
3. Takahashi N, Seki BJ, Imataka K, et al. Clinical features of paroxysmal atrial fibrillation. An observation of 94 patients. Jpn Heart J 1981;22:143-9.
4. Channer KS. The drug treatment of atrial fibrillation. Br J Clin Pharmacol 1991;32:267-73.
5. Echt DS, Liebson PR, Mitchell LB. Mortality and morbidity in patients receiving encainide, flecainide or placebo. N Engl J Med 1991;324:781-8.
6. Mason JW. Amiodarone. N Engl J Med 1987;316:455-66.
7. Lip GYH, Metcalfe MJ, Rae AP. Management of paroxysmal atrial fibrillation. Q J Med 1993;86:467-72.
8. Antonaccio MJ, Gomoll A. Pharmacology, pharmacodynamics and pharmacokinetics of sotalol. Am J Cardiol 1990;65(suppl):12-21A.
9. Hohnloser SH, Arendts W, Quart B. Incidence, type and dose-dependence of proarrhythmic events during sotalol therapy in patients treated for sustained VT/VF [abstract]. PACE Pacing Clin Electrophysiol 1992;15:551.
10. McEwan J. Manual: the Nottingham Health Profile. London: Academic Departmeni of Community Medicine, 1985.
11. Altman DG. Crossover studies. In: Practical statistics for medical research. London: Chapman and Hall, 1993:467-71.
12. Conover W. Practical nonparametric statistics. New York: Wiley, 1980.
13. Armitage P, Berry G. In: Statistical methods in medical research. London: Blackwell, 1997:115-17.
14. Schofield PM, Bennett DH. A comparison of atenolol and sotalol in the treatment of patients with paroxysmal supraventricular tachycardia [abstract]. J Am Coll Cardiol 1987;9:247.
15. Wolk R, Kulakowski P, Karczmarewicz S, et al. The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propanalol or propafenone. Int J Cardiol 1996;54:207-11.
16. Janssen J, Loomans L, Harink J. Prevention and treatment of supraventricular tachycardia shortly after coronary bypass grafting: a randomised open trial. Angiology 1986;37:601-9.
17. Suttorp MJ, Kingma JH, Gin MTJ, et al. Efficacy and safety of low and high dose sotalol versus propanalol in the prevention of supraventricular tachyarrhythmias early after coronary bypass surgery. J Thorac Cardiovasc Surg 1990; 100:921-6.
18. Mangrano DT, Layug EL, Wallace A, et al. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. N Engl J Med 1996;335:1713-20.
19. Ommen SR, Odell JA, Stanton MS. Atrial arrhythmias after cardiothoracic surgery. N Engl J Med 1997;336:1429-34.
20. Edvardsson N, Hirsch I, Emanuelsson H, et al. Sotalol-induced delayed ventricular repolarisation in man. Eur Heart J 1980;1:335-43.
21. Echt DS, Berte LE, Clusin WT, et al. Prolongation of the human cardiac monophasic action potential by sotalol. Am J Cardiol 1982;50:1082-6.
22. Touboul P, Atallah G, Kirkorian G, et al. Clinical electrophysiology of intravenous sotalol, a beta-blocking drug with class III antiarrhythmic properties. Am Heart J 1984;107:888-95.
23. Wang T, Bergstrand RH, Thompson KA, et al. Concentration-dependent pharmacologic properties of sotalol. Am J Cardiol 1986;57:1160-5.
24. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990;82:1932-9.
25. Suttorp MJ, Kingma JH, Peels HO, et al. Effectiveness of sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting. Am J Cardiol 1991;68:1163-9.
26. Bellandi F, Dabizzi RP, Niccoli I, et al. Propafenone and sotalol: long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study. Ital J Cardiol 1996;26:379-90.
27. Wanless RS, Anderson K, Joy M, et al. Multicentre comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J 1997;133: 441-6.
28. Lamb RK, Prabhakar G, Thorpe JAC, et al. The use of atenolol in the prevention of supraventricular arrhythmias following coronary artery surgery. Eur Heart J 1988;9:32-6.
29. Liprandi AS, Iglesias R, Krauss J, et al. Prevencion de arritmias supraventriculares en el postquirurgico inmediato de revascularizacion miocardica. Rev Argent Cardiol 1986;54: 21-7.
30. Naccarelli GV, Dougherty AH, Berns E, et al. Assessment of antiarrhythmic drug efficacy in the treatment of supraventricular arrhythmias. Am J Cardiol 1986;58:31-6C.